Subsequent studies encompassing larger and more homogeneous cohorts are warranted to further evaluate the effects of radiotherapy and pathway blocking drugs on PI3K/AKT/mTOR pathway downstream effectors and rarer subtypes of rectal cancer. The gene discussed is MTOR; the disease is rectal cancer.